APHINITY

NCT01358877 📎

Regimen

Experimental
Chemotherapy + trastuzumab + pertuzumab for 1 year total HER2-targeted therapy.
Control
Chemotherapy + trastuzumab + placebo for 1 year.

Population

HER2-positive early breast cancer, operable, node-positive or high-risk node-negative (pT > 1.0 cm or other high-risk features), after definitive surgery.

Key finding

APHINITY established adjuvant pertuzumab + trastuzumab + chemotherapy as standard for node-positive HER2+ early breast cancer (NCCN category 1). Updated v2.2026 NCCN Footnote mm confirms benefit at 11.3-year follow-up. Benefit limited to node-positive cohort.

Source: PMID 28581356

Timeline

  • Publication: 2017 Jul 13

Guideline citations

  • NCCN BREAST